Skip to content

TruSight Oncology 500 Portfolio

Take cancer from uncertainty to insight

Enabling comprehensive genomic profiling from tissue and liquid biopsies

TruSight Oncology 500 portfolio

The TruSight Oncology 500 portfolio consists of three research assays which enable pan-cancer comprehensive genomic profiling (CGP) for solid tumors from either blood or tissue biopsy samples. The portfolio is designed to identify relevant biomarkers in guidelines and clinical research, such as tumor mutational burden (TMB), microsatellite instability (MSI), and homologous recombination deficiency (HRD).

TruSight Oncology 500 Assay

Now with HRD* *Not available in Japan

Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS).

Learn more
TruSight Oncology 500 High-Throughput Assay

Now offered on NextSeq 1000, NextSeq 2000
and NovaSeq X Series

Batch up to 960 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.

Learn more
TruSight Oncology 500 ctDNA v2 Assay

Now offered on NovaSeq X Series

Analyze circulating tumor DNA (ctDNA) from blood plasma with a more sensitive and streamlined assay in <4 days with automation-friendly options.

Learn more

Benefits of TruSight Oncology 500 portfolio

Enable comprehensive genomic profiling
 
 
Bring the assay into your lab
 
 
Integrated, flexible, and scalable workflow
 
 
Achieve timely and reliable results
 
 

TruSight Oncology 500 portfolio brochure

As an industry leader in NGS with 25+ years of innovation, you can rely on Illumina as your preferred provider of CGP solutions. As a single supplier with expertise across the entire workflow—from library preparation to sequencing through bioinformatics—Illumina can help you efficiently enable CGP in your lab. The Illumina portfolio provides a variety of options tailored to meet the needs of your institution.

Download TSO 500 portfolio brochure​

Assay comparison

TruSight Oncology 500 TruSight Oncology 500 High-Throughput TruSight Oncology 500 ctDNA v2
FFPE (DNA and RNA) FFPE (DNA and RNA) Blood (cfDNA)
523 genes for DNA variants 523 genes for DNA variants 523 genes for DNA variants
55 genes for RNA fusions and splice variants 55 genes for RNA fusions and splice variants 23 genes for DNA fusions
Variants called:
SNVs
InDels
CNVs
Fusions
Splice variants
Genomic signatures
TMB (Immuno-Oncology)
MSI (Immuno-Oncology)
HRD - Through addition of TSO 500
HRD kit		 Variants called:
SNVs
InDels
CNVs
Fusions
Splice variants
Genomic signatures
TMB (Immuno-Oncology)
MSI (Immuno-Oncology)		 Variants called:
SNVs
InDels
CNVs
Fusions (from DNA)
Genomic signatures
TMB (Immuno-Oncology)
MSI (Immuno-Oncology)
Panel size:
1.94 Mb DNA; 358 kb RNA		 Panel size:
1.94 Mb DNA; 358 kb RNA		 Panel size:
1.94 Mb DNA
Approximate Turnaround Time:
4–5 days		 Approximate Turnaround Time:
4–5 days		 Approximate Turnaround Time:
3-4 days
Sequencing Platforms:
TSO 500 -- NextSeq 500, NextSeq 550, NextSeq550Dx in Research Mode
TSO 500 HRD -- NextSeq 550, NextSeq 550Dx in Research Mode, NovaSeq 6000 SP Flow Cell		 Sequencing Platforms:
NextSeq 1000 & 2000a
NovaSeq 6000
NovaSeq 6000Dx in RUO Mode a
NovaSeq X Seriesa		 Sequencing Platforms:
NovaSeq 6000
NovaSeq 6000Dx in RUO Mode a
NovaSeq X 
Sample Batching:

TSO 500 -- 8 samples/run
TSO 500 HRD -- 8-16 samples/run		 Sample Batching:
8-36 samples/run (NextSeq 1000 & 2000)
16–192 samples/run (NovaSeq 6000)
32-480 samples/run (NovaSeq X)
32-960 samples/run (NovaSeq X Plus)		 Sample Batching:
8–48 samples/run
Sample input:
40 ng DNA
40 ng RNA		 Sample input:
40 ng DNA
40–80 ng RNA		 Sample input:
20 ng cfDNA (10–30 ng possible)
Analytical Specificity:
99.9998%		 Analytical Specificity:
99.9998%		 Analytical Specificity:
99.9994% (SNVs)
Analytical Sensitivity:
>96%		 Analytical Sensitivity:
>96%		 Analytical Sensitivity:
>95%

aRequires a separate, stand-alone DRAGEN server for secondary analysis

Pan-cancer biomarkers

Detection of currently relevant DNA & RNA* variants for multiple types of solid tumors. Some key biomarkers include:
Pan-cancer: BRAFNTRK1 NTRK2 NTRK3RET MSI TMB
Genes with biomarkers of significance† Genes with biomarkers of potential significance‡
breast cancer Breast BRCA1 BRCA2 ERBB2 ESR1 PALB2 PIK3CA       180
colorectal cancer Colorectal ERBB2 KRAS NRAS             166
bone cancer Bone EGFR ERG ETV1 ETV4 EWSR1 FEV FLI1 FUS H3F3A 140
HEY1 IDH1 MDM2 NCOA2 SMARCB1        
lung cancer Lung ALK EGFR ERBB2 KRAS MET NUTM1 ROS1     223
melanoma cancer Melanoma KIT NRAS ROS1             172
ovarian cancer Ovarian BRCA1 BRCA2 FOXL2             149
cns cancer CNS APC ATRX CDKN2A CDKN2B EGFR H3F3A HIST1H3B HIST1H3C IDH1 140
IDH2 MYCN PTCH1 RELA TERT TP53      
prostate cancer Prostate AR ATM BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2 151
FANCL FGFR2 FGFR3 PALB2 RAD51B RAD51C RAD51D RAD54L  
thyroid cancer Thyroid HRAS KRAS NRAS RET TERT         165
uterine cancer Uterine & cervical BRCA2 EPC1 ERBB2 ESR1 FOXO1 GREB1 JAZF1 NCOA2 NCOA3 138
NUTM2A NUTM2B PAX3 PAX7 PHF1 POLE SMARCA4 SUZ12 TP53
YWHAE                
other solid cancer tumors Other Solid Tumors ALK APC ARID1A ASPSCR1 ATF1 ATIC BAP1 BCOR BRCA1 152
BRCA2 CAMTA1 CARS CCNB2 CDK4 CDKN2A CIC CITED2 CLTC
COL1A1 COL6A3 CREB1 CREB3L1 CREB3L2 CSF1 CTNNB1 DDIT3 DDX3X
DNAJB1 DUX4 EED EGFR ERBB2 ERG ETV1 ETV4 ETV6
EWSR1 FEV FGFR2 FGFR3 FLI1 FOXL2 FOXO1 FOXO4 FUS
GLI1 HEY1 HGF HMGA2 IDH1 KRAS LEUTX MAML3 MDM2
MYB MYOD1 NAB2 NCOA2 NF1 NFATC2 NFIB NR4A3 NRAS
NUTMI NUTM2A NUTM2B PALB2 PATZ1 PAX3 PAX7 PDGFB PDGFRA
PRKACA PRKD1 RANBP2 ROS1 SDHA SDHB SDHC SDHD SMARCB1
SS18 SSX1 SSX2 SSX4 STAT6 SUZ12 TAF15 TCF12 TERT
TFE3 TFEB TFG TP53 TPM3 TPM4 TRAF7 TSPAN31 VGLL2
WT1 WWTR1 YAP1 YWHAE ZC3H7B        

The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.

* RNA variants only called from TSO 500 and TSO 500 HT assays.

† The product to evaluate DNA & RNA variants is the TruSight Oncology 500 DNA/RNA Bundle.

Illumina NGS Methods Guide

Analytical evaluation guidance

The TruSight Oncology 500 analytical guidance expedites implementation with recommendations intended to align with the latest industry standards and best practices.

View guidance

Have questions about our products? Connect with an Illumina representative.

For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2024 Illumina, Inc. All rights reserved.